Table 1. Clinical characteristics and miRNA-15a/-16-1 expression in newly diagnosed patients.

Characteristics	N (%)	miRNA-15a (mean ± SD)	P-value	miRNA-16-1 (mean ± SD)	P-value
Durie-Salmon stage			0.325		0.196
I-II	10 (11.6)	3.05 ± 1.47		2.81 ± 0.75
III	76 (88.4)	3.44 ± 0.93		2.85 ± 0.73
ISS stage			0.532		0.240
I-II	37 (43.0)	3.42 ± 1.09		2.80 ± 0.76
III	49 (57.0)	3.38 ± 0.92		2.99 ± 0.76
LDH, U/L			0.668		0.661
≥ 220	18 (22.5)	3.42 ± 1.08		2.91 ± 0.87
< 220	62 (77.5)	3.38 ± 0.99		2.83 ± 0.75
Renal lesion			0.577		0.179
no	66 (75.9)	3.40 ± 0.99		2.70 ± 0.33
yes	21 (24.1)	3.35 ± 1.00		3.02 ± 0.86
Del(13q)			0.436		0.337
no	60 (66.7)	3.40 ± 1.03		2.81 ± 0.67
yes	30 (33.3)	3.43 ± 0.93		2.84 ± 0.87
Del(17p)			0.874		0.663
no	78 (88.6)	3.50 ± 1.02		2.85 ± 0.76
yes	10 (11.4)	3.00 ± 0.63		2.58 ± 0.63
Amp(1q21)			0.091		0.215
no	38 (46.3)	3.59 ± 0.86		2.99 ± 0.80
yes	44 (53.7)	3.20 ± 1.05		2.70 ± 0.67
IGH translocation			0.702		0.990
no	34 (39.5)	3.50 ± 1.16		2.80 ± 0.90
yes	52 (60.5)	3.38 ± 0.89		2.89 ± 0.66
t(11;14)			0.221		0.860
no	66 (82.5)	3.38 ± 1.04		2.72 ± 0.78
yes	14 (17.5)	3.42 ± 0.61		2.96 ± 0.47
t(4;14)			0.474		0.151
no	64 (80.0)	3.41 ± 0.96		2.85 ± 0.78
yes	16 (20.0)	3.11 ± 0.98		2.70 ± 0.58
t(14;16)			0.216		0.796
no	74 (93.7)	3.42 ± 0.98		2.87 ± 0.72
yes	5 (6.3)	2.68 ± 0.66		1.90 ± 0.30
High-risk [(any t(4;14), t(14;16) or del(17p)]			0.137		0.060
no	60 (73.2)	3.62 ± 0.93		2.85 ± 0.77
yes	22 (26.8)	3.00 ± 0.88		2.70 ± 0.59
Disease progression			0.040		0.347
no	60 (69.0)	3.46 ± 0.92		2.97 ± 0.64
yes	27 (31.0)	3.28 ± 1.13		2.68 ± 0.93
Dead			0.012		0.145
no	67 (77.9)	3.46 ± 0.91		2.85 ± 0.72
yes	19 (22.1)	3.06 ± 0.94		2.60 ± 0.62

ISS, International Staging System